🇺🇸 FDA
Patent

US 10980797

Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

granted A61KA61K2039/505A61K31/444

Quick answer

US patent 10980797 (Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors) held by Corcept Therapeutics Incorporated expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K31/444, A61K31/4745, A61K31/57